Angina Pectoris Drugs Market Size Projected To Increase From $13.62 Billion To $17.66 Billion During The Forecast Period
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Angina Pectoris Drugs Market Forecast Highlighting Growth From $13.62 Billion To $17.66 Billion
The market for angina pectoris medications has demonstrated robust expansion over the past few years, with its value projected to increase from $12.88 billion in 2025 to $13.63 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.8%. This growth trajectory during the historic period has been largely shaped by the rising incidence of coronary heart disease, heightened public awareness of angina symptoms, the introduction of beta-blockers, improvements in hospital infrastructure, and a growing preference for calcium channel blockers.
The angina pectoris drugs market anticipates robust expansion in the coming years, with projections indicating growth to $17.67 billion by 2030, representing a compound annual growth rate (CAGR) of 6.7%. This forecast period growth is driven by factors including progress in precision medicine, the proliferation of wearable cardiac monitoring devices, increasing demand for combination therapies, elevated investment in research and development for anti-ischemic agents, and the incorporation of telehealth into cardiac care. Notable trends expected to shape this period comprise personalized approaches to angina management, minimally invasive drug delivery systems, fixed-dose combination therapies, a rising elderly demographic, and telemedicine combined with remote cardiac care.
Download A Free Sample Report For Comprehensive Market Insights:
Angina Pectoris Drugs Market Growth Factors Supporting Long-Term Expansion
The anticipated rise in cardiovascular disease cases is set to fuel expansion within the angina pectoris drug market moving forward. These diseases involve a variety of disorders affecting the heart and blood vessels, including coronary artery disease, hypertension, heart failure, and stroke. This upward trend in cardiovascular disease prevalence is driven by factors such as an older demographic, poor lifestyle choices, and the growing obesity crisis. Medications for angina pectoris, including nitrates, beta-blockers, and calcium channel blockers, are effective at alleviating chest pain and discomfort stemming from inadequate blood flow to the heart, thus improving patients’ quality of life. For example, in January 2024, data from the American Heart Association, a US nonprofit, showed that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the growing burden of cardiovascular diseases is accelerating the angina pectoris drug market’s growth.
The rising prevalence of diabetes is expected to drive expansion in the angina pectoris drug market over the forthcoming period. Hypertension, commonly referred to as high blood pressure, is a medical condition involving abnormally high arterial blood pressure, while diabetes is a chronic disease characterized by elevated blood glucose levels. Both conditions are common risk factors for cardiovascular issues like angina pectoris. As these illnesses become more widespread, the need for angina medications intensifies. For instance, in June 2024, the National Health Service, a UK government entity, reported that in 2023, it identified over half a million (549,000) new individuals in England at risk of type 2 diabetes, raising the total number of people with non-diabetic hyperglycemia, or pre-diabetes, recorded with a GP to 3,615,330. This marks a nearly 20% increase from 3,065,825 in 2022. Hence, the growing rates of diabetes are propelling the angina pectoris drug market forward.
Angina Pectoris Drugs Market Categorization By Product Type And Application
The angina pectoris drugs market covered in this report is segmented –
1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates
2) By Antiplatelet Agents: Aspirin, Clopidogrel
3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers
4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers
5) By Anti-Ischemic Agents: Ranolazine, Ivabradine
6) By Statins: Atorvastatin, Rosuvastatin
Angina Pectoris Drugs Market Industry Trends Shaping Future Revenue Growth
Leading players in the angina pectoris drug market are increasingly turning to technological innovations to maintain their competitive edge, exemplified by the U.S. Food and Drug Administration’s clearance of Labetalol Hydrochloride Injection for managing angina and improving customer outcomes. Nitrostat (Nitroglycerin Sublingual Tablets) has received approval from the U.S. Food and Drug Administration (FDA) for the prompt management of angina pectoris or its acute prevention. A case in point is March 2023, when Hikma Pharmaceuticals PLC, a pharmaceutical firm based in the UK, introduced Labetalol Hydrochloride Injection, USP, available in a prefilled syringe. This product has been granted approval by the United States FDA. Within hospital settings, the 10 mg/2 mL PFS is employed to address severe hypertension and facilitate blood pressure reduction.
Angina Pectoris Drugs Market Company Landscape And Strategic Competition
Major companies operating in the angina pectoris drugs market are Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Bausch Health Companies Inc., Merck & Co Inc., Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, Sun Pharmaceutical Industries Limited, Sanofi SA, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., GlaxoSmithKline plc, Lupin Pharmaceuticals Inc., Merck KGaA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB S.A., Servier Laboratories, Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., H. Lundbeck A/S
Access The Complete Angina Pectoris Drugs Market Report:
Angina Pectoris Drugs Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the angina pectoris drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angina pectoris drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
